U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Wed Apr 02 15:39:07 GMT 2025
Edited
by admin
on Wed Apr 02 15:39:07 GMT 2025
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IGG1|LAMDA|KAPPA
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
BL5C53FB6H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
H-gamma1 heavy chain anti-MET Homo sapiens (1-446) [VH (Homo sapiens IGHV1-8*01 (95.9%) -(IGHD) -IGHJ3*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v33
Preferred Name English
Tilatamig Samrotecan
Common Name English
immunoglobulin G1-kappa/G1-lambda, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)]
Common Name English
tilatamig samrotecan [INN]
Common Name English
Immunoglobulin G1 [133-cysteine,227-valine,241-phenylalanine,242-glutamic acid,338-serine, 361-cysteine,373-tryptophan], anti-(human epidermal growth factor receptor) (human monoclonal RAA22 ?1-chain), (133?126??)-disulfide with [126-cysteine,216-valine]
Common Name English
TILATAMIG SAMTOTECAN [USAN]
Common Name English
Code System Code Type Description
SMS_ID
300000048255
Created by admin on Wed Apr 02 15:39:07 GMT 2025 , Edited by admin on Wed Apr 02 15:39:07 GMT 2025
PRIMARY
CAS
2868265-77-2
Created by admin on Wed Apr 02 15:39:07 GMT 2025 , Edited by admin on Wed Apr 02 15:39:07 GMT 2025
PRIMARY
NCI_THESAURUS
C192091
Created by admin on Wed Apr 02 15:39:07 GMT 2025 , Edited by admin on Wed Apr 02 15:39:07 GMT 2025
PRIMARY
USAN
NO-14
Created by admin on Wed Apr 02 15:39:07 GMT 2025 , Edited by admin on Wed Apr 02 15:39:07 GMT 2025
PRIMARY
INN
13021
Created by admin on Wed Apr 02 15:39:07 GMT 2025 , Edited by admin on Wed Apr 02 15:39:07 GMT 2025
PRIMARY
FDA UNII
BL5C53FB6H
Created by admin on Wed Apr 02 15:39:07 GMT 2025 , Edited by admin on Wed Apr 02 15:39:07 GMT 2025
PRIMARY
From To
4_134 4_194
4_23 4_88
3_139 3_198
3_22 3_90
2_366 2_424
2_260 2_320
2_143 2_219
2_22 2_96
1_361 2_348
1_374 1_432
1_268 1_328
1_151 1_207
1_133 3_126
1_22 1_96
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_304
N 2_296
Related Record Type Details
HEPATOCYTE GROWTH FACTOR RECEPTOR
TARGET->LIGAND
Related Record Type Details
Tilatamig Samrotecan
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID REMOVAL [1_454] [2_446] C-TERMINUS LYSINE K3Z4F929H6
AMINO_ACID_SUBSTITUTION RESIDUE_SPECIFIC C Amount: Cysteinyl samrotecan ZJ5SH7K3UK
AMINO_ACID_SUBSTITUTION [1_1] [2_1] N-TERMINUS PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966